Background and Aim: In psoriasis, the proteins Tumor Necrosis Factor (TNF) and interleukin-6 (IL-6) are overexpressed and play important roles in the disease's progression. For treating psoriasis, biological drugs that target TNF signaling are quite successful. Embryogenesis, tissue repair, cancer, neuronal survival, host defense, and inflammation are all dependent on progranulin (PGRN). By competing with TNF binding to TNFR1/2, PGRN inhibits TNF-mediated signaling pathways and has anti-inflammatory properties in inflammatory arthritis models. The current research seeks to study the relationship between serum PGRN / TNF - \(\alpha\)and psoriasis vulgaris activity. Subjects & Methods: This study’s subjects were categorized into 2 groups: group 1 with 35 patients with psoriasis vulgaris, and group 2 of 30 healthy subjects with matched age and sex. Results: We discovered a significant increase in PGRN and TNF-\(\alpha\)in cases versus control. And we have found a significant decrease in PGRN/TNF-\(\alpha\)ratio in cases versus control. We also detected significant differences between the Psoriasis Area Severity Index (PASI) degree and the levels of PGRN and TNF-\(\alpha\), as well as the PGRN/TNF-\(\alpha\)ratio. We discovered a negative significant correlation between PASI and PGRN/TNF-\(\alpha\)ratio. Conclusion: Atsttrin exhibited potent anti-inflammatory properties due to its three modified granulin motifs and their associated linker regions. In the treatment of rheumatoid arthritis and contact dermatitis, PGRN and its derivative Atsttrin may be a potential therapeutic drug.

Background: Progranulin (PGRN) has significant functions in several processes, including immune response and the development of cancer. This study aims to research the relationship between the ratio of serum progranulin/tumor necrosis factor (TNF) alpha and the rheumatoid arthritis (RA) activity. Methods: This study included 35 patients with rheumatoid arthritis whom we collected their complete history with personal and family history included in addition to 30 seemingly healthy individuals as a normal control group. In addition to clinical examinations, laboratory tests, and serum progranulin level and TNF-alpha by the Enzyme-linked Immunosorbent Assay (ELISA). Results: There were significant increases in Erythrocyte Sedimentation Rate (ESR), C-reactive protein (CRP), Rheumatoid Factor (RF), PGRN and TNF alpha in the diseased group compared to the control group. The serum levels of PGRN and TNF alpha in the rheumatoid arthritis community were significantly higher than in the control group. In the RA community, there was a positive association between the PGRN/TNF alpha ratio and Disease Activity Score in 28 joints (DAS28) score and RF. The relationship between PGRN and the severity ratio was significant. The relationship between TNF alpha and the severity ratio of the disease were highly significant. Also, a significant relationship between the PGRN/TNF alpha ratio and DAS28 score was significant. Conclusion: An important correlation between circulating levels of PGRN and TNF-alpha, and activity of the disease was in RA patients.